Risk of an Undeveloped Sales Framework for Regenerative Medical Products
First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual reportIn the FY2024 business risk section, the risk of an inadequate sales system for regenerative medicine products cannot be confirmed as a separate item.
- FY2020RestatedAnnual report
「The company plans to further strengthen its sales system in preparation for market expansion driven by new products and expanded indications, including increasing the number of sales representatives, improving the efficiency of sales methods and reviewing logistics. However, if the market expands too rapidly, the strengthening of the system may not keep pace, leaving the company unable to handle all orders.」
The company continues to pursue plans to strengthen its sales representatives, sales methods and logistics in preparation for new products and expanded indications, while identifying the risk of delayed responses if the market expands rapidly. - FY2019RestatedAnnual report
「The company plans to further strengthen its sales system in preparation for market expansion driven by new products and expanded indications, including increasing the number of sales representatives, improving the efficiency of sales methods and reviewing logistics. However, if the market expands too rapidly, the strengthening of the system may not keep pace, leaving the company unable to handle all orders.」
The company states its policy of increasing the number of sales representatives, improving sales methods and reviewing logistics in preparation for new products and expanded indications, while also identifying the risk of delayed responses if the market expands rapidly. - FY2016First statedAnnual report
「However, if the development of the sales system does not progress as planned, sales may not be recorded in line with the plan.」
The company identifies as challenges the need to establish sales infrastructure differing from that for conventional pharmaceuticals and medical devices, including providing information to medical institutions, make-to-order production, logistics, safety management and post-marketing surveillance.